Adjuvant radioimmunotherapy improves survival of rats after resection of colorectal liver metastases

Annals of Surgery

Volumn 253, Issue 2, 2011, Pages 336-341

  De Jong, Gabie M ^a   Hendriks, Thijs ^a   Eek, Annemarie ^b   Oyen, Wim J G ^b   Nagtegaal, Iris D ^b   Bleichrodt, Robert P ^a   Boerman, Otto C ^b  

^a Division of Abdominal and Oncological Surgery   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MG1 IN 111; MONOCLONAL ANTIBODY MG1 LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; UPC 10 LU 177;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG UPTAKE; INTESTINE; KIDNEY; LIVER; LIVER METASTASIS; LIVER RESECTION; LUNG; MALE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; RAT; RECURRENT CANCER; SPLEEN; THYMUS;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; HEPATECTOMY; INDIUM RADIOISOTOPES; LIVER NEOPLASMS; LUTETIUM; MALE; NEOPLASM RECURRENCE, LOCAL; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOTHERAPY, ADJUVANT; RATS; RATS, INBRED STRAINS; SURVIVAL RATE;

EID: 79151483232     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181ff313a     Document Type: Article

References (41)

1. National Cancer Institute. U.S. International Institutes of Health. Available at: http://www.cancer.gov/cancertopics/types/colon-and-rectal. Accessed October 8, 2009.
2. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77:1241-1246.
3. Nordlinger B, Van CE, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20:985-992.
4. SmithMD,McCall JL. Systematic review of tumour number and outcome after radical treatment of colorectal livermetastases. Br J Surg. 2009;96:1101-1113.
5. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982-999.
6. Kavolius J, Fong Y, Blumgart LH. Surgical resection ofmetastatic liver tumors. Surg Oncol Clin N Am. 1996;5:337-352.
7. Nanko M, Shimada H, Yamaoka H, et al. Micrometastatic colorectal cancer lesions in the liver. Surg Today. 1998;28:707-713.
8. Panis Y, Ribeiro J, Chretien Y et al. Dormant liver metastases: an experimental study. Br J Surg. 1992;79:221-223.
9. Koch M, Kienle P, Hinz U, et al. Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann Surg. 2005;241:199-205.
10. Ruers T, Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer. 2002;38:1023-1033.
11. Behr TM, Salib AL, Liersch T, et al. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study. Clin Cancer Res. 1999;5:3232s-3242s. (Pubitemid 29493921)
12. Koppe MJ, SoedeAC, PelsW, et al. Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. Int J Cancer. 2003;106:965-972.
13. Aarts F, Hendriks T, Boerman OC, et al. A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats. Ann Surg Oncol. 2007;14:3274-3282.
14. Fidarova EF, El-Emir E, Boxer GM, et al. Microdistribution of targeted, fluorescently labeled anti-carcinoembryonic antigen antibody in metastatic colorectal cancer: implications for radioimmunotherapy. Clin Cancer Res. 2008;14:2639-2646.
15. Sato N, Saga T, Sakahara H, et al. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse. J Nucl Med. 1999;40:685-692.
16. HagenaarsM, Koelemij R, Ensink NG, et al. The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma. Clin Exp Metastasis. 2000;18:281-289.
17. Koppe MJ, Hendriks T, Boerman OC, et al. Radioimmunotherapy is an effective adjuvant treatment modality after cytoreductive surgery of peritoneal carcinomatosis of colonic origin. J Nucl Med. 2006;47:1867-1874.
18. de Jong GM, Hendriks T, Eek A, et al. Radioimmunotherapy improves survival of rats with microscopic liver metastases of colorectal origin. Ann Surg Oncol. 2009;16:2065-2073.
19. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318.
20. Lopes Cardozo AM, Gupta A, Koppe MJ, et al. Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats. Eur J Surg Oncol. 2001;27:359-363.
21. de Jong GM, Aarts F, Hendriks T, et al. Animal models for liver metastases of colorectal cancer: research review of preclinical studies in rodents. J Surg Res. 2009;154:167-176.
22. Martins PN, Theruvath TP, Neuhaus P. Rodent models of partial hepatectomies. Liver Int. 2008;28:3-11.
23. de Jong GM, Boerman OC, Heskamp S, et al. Radioimmunotherapy prevents local recurrence of colonic cancer in an experimental model. Br J Surg. 2009;96:314-321.
24. Scheele J, Stang R, tendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg. 1995;19:59-71.
25. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938-946.
26. Pawlik TM. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715-724.
27. Neeleman N, Andersson R. Repeated liver resection for recurrent liver cancer. Br J Surg. 1996;83:893-901.
28. Imamura H, Kawasaki S, Miyagawa S, et al. Aggressive surgical approach to recurrent tumors after hepatectomy for metastatic spread of colorectal cancer to the liver. Surgery. 2000;127:528-535.
29. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26:4906-4911.
30. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007-1016.
31. Petrelli NJ. Perioperative or adjuvant therapy for resectable colorectal hepatic metastases. J Clin Oncol. 2008;26:4862-4863.
32. Nelson R, Freels S. Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver. Cochrane Database Syst Rev. 2006;CD003770.
33. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non- Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 2001;39:195-201.
34. Behr TM, Memtsoudis S, Vougioukas V, et al. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial. Anticancer Res. 1999;19: 2427-2432.
35. Liersch T, Meller J, Kulle B, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol. 2005;23:6763-6770.
36. Liersch T, Meller J, Bittrich M, et al. Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol. 2007;14:2577-2590.
37. Liersch T, Meller J, Sahlmann CO. Efficacy of repeated anti-CEAradioimmunotherapy (RAIT) with 131Iodine(I)-labetuzumab (phase II study) in patients with colorectal cancer (CRC) after salvage resection of multiple liver metastases (CRC-LM). Presented at the proceedings of the Gastrointestinal Cancers Symposium; January 15-17, 2009; San Francisco, CA. Abstract.
38. Ychou M, Azria D, Menkarios C, et al. Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab-)2 after resection of liver metastases from colorectal cancer. Clin Cancer Res. 2008;14:3487-3493.
39. Behr TM, Goldenberg DM, Becker WS. Radioimmunotherapy of solid tumors: a review "of mice and men". Hybridoma. 1997;16:101-107.
40. Aarts F, Koppe MJ, Hendriks T, et al. Timing of adjuvant radioimmunotherapy after cytoreductive surgery in experimental peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2007;14:533-540.
41. Aarts F, Bleichrodt RP, de MB, et al. The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat. Ann Surg Oncol. 2008;15: 3299-3307.